HR (95% CI) | P values | HR (95% CI) | P values | |
Outcome: composite endpoint | ||||
LVEF | 0.94 (0.93 to 0.95) | <0.001 | 0.96 (0.93 to 0.99) | 0.028 |
e′ septal | 0.85 (0.78 to 0.92) | <0.001 | 0.68 (0.48 to 0.97) | 0.034 |
E/e′ septal | 1.04 (1.02 to 1.05) | <0.001 | 1.09 (1.02 to 1.16) | 0.012 |
EDP/LVEDVI ratio×10 | 0.72 (0.59 to 0.88) | 0.001 | 1.39 (1.00 to 1.92) | 0.047 |
EDP/LAVI ratio×10 | 0.80 (0.69 to 0.93) | 0.004 | 1.62 (1.16 to 1.23) | 0.004 |
Global longitudinal LV strain, % | 1.19 (1.13 to 1.25) | <0.001 | 1.15 (0.98 to 1.35) | 0.09 |
The composite endpoint was defined as the composite outcome of left ventricular assistant device implantation, heart transplantation or all-cause mortality.
CPET, cardiopulmonary exercise testing; CTHF, cancer therapy-induced heart failure; EDP, end-diastolic pressure; LAVI, left atrial volume index; LV, left ventricular; LVEF, left ventricular ejection fraction; LVEDVI, left ventricular end-diastolic volume index; NCTHF, non-cancer therapy-induced heart failure.